SOPHiA GENETICS (SOPH) CEO gets major option and RSU grants, corrects holdings

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported awards of share-based incentives and corrected his reported holdings. He received a share option for 628,743 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036.

He was also granted 431,211 restricted stock units, each representing one ordinary share, under the 2021 Equity Incentive Plan. Following these grants, his beneficially owned ordinary shares are correctly reported as 3,734,050, revising a previously misstated amount in an earlier Form 4.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Camblong Jurgi

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	628,743	$0.00	--
Grant/Award	Ordinary Shares	431,211	$0.00	--

Holdings After Transaction: Share Option (Right to Buy) — 628,743 shares (Direct); Ordinary Shares — 3,734,050 shares (Direct)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 431,211 ordinary shares due to an inadvertent error. The correct amount is 3,734,050 ordinary shares. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Key Figures

Option grant size: 628,743 options Option exercise price: $5.04 per share Option expiration: April 2, 2036 +3 more

6 metrics

Option grant size 628,743 options Share Option (Right to Buy) granted on April 2, 2026

Option exercise price $5.04 per share Exercise price for 628,743-share option grant

Option expiration April 2, 2036 Expiration date of CEO share option grant

RSU grant size 431,211 RSUs Ordinary share RSU grant on April 2, 2026

Shares owned after grant 3,734,050 ordinary shares Beneficially owned following reported transactions

RSU initial vesting 25% on April 2, 2027 First vesting tranche of CEO RSU grant

Key Terms

restricted stock unit ("RSU"), 2021 Equity Incentive Plan, beneficially owned, share option

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."

2021 Equity Incentive Plan financial

"RSU grant made under the Issuer's 2021 Equity Incentive Plan."

beneficially owned financial

"correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction)"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

share option financial

"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Camblong Jurgi

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/03/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/02/2026		A		431,211(1)	A	$0	3,734,050(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$5.04	04/02/2026		A		628,743		(3)	04/02/2036	Ordinary Shares	628,743	$0	628,743	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

2. This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 431,211 ordinary shares due to an inadvertent error. The correct amount is 3,734,050 ordinary shares.

3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Remarks:

	/s/ Elimara Brunetto as Attorney-in- Fact for Jurgi Camblong	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did SOPHiA GENETICS (SOPH) report for CEO Jurgi Camblong?

The CEO reported two equity awards: a share option for 628,743 ordinary shares at a $5.04 exercise price and a grant of 431,211 restricted stock units. Both awards were acquired at no cash price as part of the company’s equity plan.

How many SOPHiA GENETICS (SOPH) shares does the CEO hold after this Form 4/A?

After the reported transactions, the CEO beneficially owns 3,734,050 ordinary shares. This Form 4/A specifically corrects a prior filing that had mistakenly reported his post-transaction holdings as 431,211 ordinary shares instead of the correct higher figure.

What are the key terms of the SOPHiA GENETICS (SOPH) stock option granted to the CEO?

The CEO received a share option covering 628,743 ordinary shares with a $5.04 exercise price per share, expiring on April 2, 2036. The option vests 25% on April 2, 2027, with the remaining shares vesting in equal monthly installments through April 2, 2030.

How do the SOPHiA GENETICS (SOPH) RSUs granted to the CEO vest over time?

The CEO was granted 431,211 restricted stock units, each tied to one ordinary share. Twenty-five percent vest on April 2, 2027, and the remaining 75% vest in equal quarterly installments through April 2, 2030, subject to his continued service with the company.

Why was this SOPHiA GENETICS (SOPH) Form 4/A filed as an amendment?

This Form 4/A amends a Form 4 filed April 3, 2026 to correct the amount of ordinary shares beneficially owned after the transactions. The earlier filing mistakenly showed 431,211 shares; the accurate post-transaction holding is 3,734,050 ordinary shares.